cytarabine has been researched along with fludarabine in 310 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (1.29) | 18.7374 |
| 1990's | 61 (19.68) | 18.2507 |
| 2000's | 122 (39.35) | 29.6817 |
| 2010's | 100 (32.26) | 24.3611 |
| 2020's | 23 (7.42) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Björck, L; Clausen, AR; Piskur, J; Sandrini, MP; Shannon, O | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Gandhi, V; Plunkett, W | 4 |
| Gandhi, V; Keating, M; Kemena, A; Plunkett, W; Shewach, DS | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Gandhi, V; Keating, MJ; Kemena, A; Plunkett, W | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Danhauser, L; Gandhi, V; Plunkett, W | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P | 1 |
| Escudier, SM; Seymour, JF | 1 |
| Estey, E; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
| Carrara, P; Cenacchi, A; Clavio, M; Gamberi, B; Manfroi, S; Ottaviani, E; Testoni, N; Tosi, P; Visani, G; Zinzani, PL | 1 |
| Manfori, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; Li, YY; McLaughlin, P; O'Brien, S; Robertson, LE | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Estey, E; Gandhi, V; Plunkett, W | 1 |
| Allegra, CJ; Chabner, BA; Chu, E; Grem, JL; Johnston, PG; Takimoto, CH; Van Groeningen, C | 1 |
| Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Gandhi, V | 1 |
| Gandhi, V; Keating, MJ; Plunkett, W; Robertson, LE | 1 |
| Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J | 1 |
| McCulloch, EA; Rayappa, C | 1 |
| Beran, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Rios, MB; Suki, S | 1 |
| Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 2 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Archimbaud, E; Thomas, X | 1 |
| Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S | 1 |
| Estey, EH; Kantarjian, HM; Keating, MA | 1 |
| Hapke, DM; Mitchell, BS; Stegmann, AP | 1 |
| Bernabei, PA; D'Ippolito, G; Ermini, A; Rossi-Ferrini, P; Santini, V; Zoccolante, A | 1 |
| Gandhi, V; Loughlin, S; Plunkett, W; Zwelling, LA | 1 |
| Estey, EH; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Estey, E; Kuschel, B | 1 |
| Wiley, JS | 1 |
| Baldwin, SA; Beaumont, N; Boumah, CE; Cass, CE; Coe, I; Davies, A; Griffiths, M; Kwong, FY; Sundaram, M; Yao, SY; Young, JD | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Huang, P; Iwasaki, H; Keating, MJ; Plunkett, W | 1 |
| Cohen, JD; Katz, TB; Marcel, PD; Strock, DJ; Teik, JE | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Heitjan, DF | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S | 1 |
| Bertone, A; Candoni, A; Grattoni, R; Russo, D; Zaja, F | 1 |
| Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V | 1 |
| Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Gandhi, V; Huang, P; Plunkett, W; Seymour, JF | 1 |
| Estey, EH | 2 |
| Bosanquet, AG | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Callet Bauchu, E; Dumontet, C; Fabianowska-Majewska, K; Fang, X; Gandhi, V; Gazzo, S; Lepoivre, M; MacKey, J; Mantincic, D; Peters, GJ; Rolland, MO; Tigaud, I; Vanier-Viornery, A; Voorn, DA; Wyczechowska, D | 1 |
| Ahmed, N; Baumforth, KR; Hassan, HT; Laverick, L; Sammons, J | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Gandhi, V; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Robertson, LE; Santini, V; Seymour, JF | 1 |
| Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S | 1 |
| Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S | 1 |
| Braess, J; Hiddemann, W; Jahns-Streubel, G; Kern, W; Keye, S; Schleyer, E; Unterhalt, M; Wegendt, C | 1 |
| Januszewicz, EH; Juneja, S; Prince, HM; Seymour, C; Strickland, AH; Wolf, M | 1 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Higashi, Y; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Carbone, GM; Catapano, CV; Fernandes, DJ | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Ariola, C; Cordone, I; Fazi, F; Fenu, S; Mandelli, F; Montefusco, E; Nanni, M; Petti, MC; Spadea, A; Spiriti, MA | 1 |
| Carella, AM; Carotenuto, M; Cascavilla, N; D'Arena, G; Greco, MM; Ladogana, S; Melillo, L; Perla, G; Sajeva, MR | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Ehninger, G; Fiedler, F; Friedrichsen, K; Hänel, A; Hänel, M; Herbst, R; Morgner, A; Neser, S; Nicklisch, M; Teich, M | 1 |
| Johnson, SA | 1 |
| Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
| Kashyap, A; Snowden, J | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Appelbaum, FR | 1 |
| Fezoui, H; Genet, P; Lionnet, F; Louvel, D; Pulik, M; Touahri, T | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M | 1 |
| Andreeff, M; Cortes, JE; Faderl, S; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Tsimberidou, AM | 1 |
| de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Antoun, S; Carpiuc, I; Delabarthe, A; Driss, B; Fenaux, R; Griscelli, F; Ribrag, V; Vantelon, JM | 1 |
| Chamorey, AL; Milano, G; Thyss, A | 1 |
| Gajewski, JL; Hicks, K; Peng, D | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Robak, T | 1 |
| Lucas, T; Samorapoompichit, P; Schedled, A; Sperr, WR; Steiner, M; Valent, P; Wachtler, F | 1 |
| Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y | 1 |
| Björkstrand, B; Gruber, A; Johnsen, HE; Pelliniemi, TT; Rasmussen, T; Remes, K | 1 |
| Baker, RJ; Foroni, L; Ganeshaguru, K; Jones, DT; Mehta, AB; Mitchell, WA; Prentice, HG; Wickremasinghe, RG | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Cotter, M; Enright, H | 1 |
| Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Brando, B; Cafro, AM; Cairoli, R; D'Avanzo, G; Farioli, R; Intropido, L; Montillo, M; Morra, E; Pungolino, E; Rossi, V; Scarpati, B; Tedeschi, A; Veronese, S | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Bongarzoni, V; Buffolino, S; Cimino, G; Montanaro, M; Niscola, P; Scaramucci, L | 1 |
| Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH | 1 |
| Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
| Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E | 1 |
| Holyoake, TL; McQuaker, IG; Osborne, WL; Parker, AN | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Broekhuizen, R; Cloos, J; Creutzig, U; Fleischhack, G; Haarman, EG; Hubeek, I; Huismans, DR; Kaspers, GJ; Litvinova, E; Peters, GJ; Zwaan, CM | 1 |
| Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ | 1 |
| Abdall, N; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gatto, S; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R; Venturino, C | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Naito, K; Ohnishi, K | 1 |
| Dumontet, C; Galmarini, CM; Jordheim, LP | 1 |
| Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G | 1 |
| Bao, L; Huang, XJ; Jiang, B; Lu, DP; Lu, J; Lu, XJ; Qiu, JY; Shi, HX; Wang, DB; Wang, FR | 1 |
| Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J | 1 |
| Hori, H; Kawai, Y; Ueda, T; Yoshio, N | 1 |
| Albertioni, F; Löfgren, C; Paul, C | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Ball, ED; Bashey, A; Carrier, E; Castro, JE; Corringham, S; Hassidim, K; Holman, P; Ihasz, A; Keese, K; Lane, TA; Liu, L; Medina, B | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Asano, S; Iseki, T; Konuma, T; Nakaoka, T; Ooi, J; Takahashi, S; Takasugi, K; Tojo, A; Tomonari, A; Tsukada, N; Uchiyama, M | 1 |
| Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F | 1 |
| Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC | 1 |
| Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M | 1 |
| Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK | 1 |
| Benedetti, F; Boccadoro, M; Chisesi, T; De Blasio, A; Drandi, D; Gallamini, A; Ladetto, M; Locasciulli, A; Majolino, I; Tarella, C | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Iwasaki, H; Kawai, Y; Kishi, S; Takemura, H; Ueda, T; Urasaki, Y; Yamamoto, S; Yamauchi, T; Yoshida, A | 1 |
| Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y | 1 |
| Arakawa, S; Hamanoue, S; Inoue, H; Ishiguro, H; Katob, S; Koike, T; Masukawa, A; Matsumoto, M; Miyachi, H; Morimoto, T; Ohshima, T; Yabe, H; Yabe, M; Yamashita, T | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M | 1 |
| Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B | 1 |
| Brown, JR; Estrov, Z; Ferrajoli, A; Fiorentino, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Kipps, TJ; Kurzrock, R; Lerner, S; O'Brien, S; Plunkett, W; Ravandi-Kashani, F; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W | 1 |
| Atra, AA; Baothman, A; Elimam, NA; Kassar, A; Khattab, TM; Zayed, A | 1 |
| Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E | 1 |
| Fujimori, Y; Hara, H; Ikegame, K; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Ogawa, H; Okada, M; Okikawa, Y; Satake, A; Takatsuka, H; Tamaki, H | 1 |
| Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
| du Toit, C; McDonald, A; Novitzky, N; Thomas, V | 1 |
| Chen, ZC; Li, QB; Li, WM; Xia, LH; You, Y; Zhou, H; Zou, P | 1 |
| Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A | 1 |
| Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH | 1 |
| Boyer, SH; Erion, MD; Linemeyer, DL; MacKenna, DA; Montag, A | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Bruns, I; Czibere, A; Fenk, R; Gräf, T; Haas, R; Kobbe, G; Schroeder, T; Zohren, F | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Hong, M; Li, JY; Li, Q; Lu, H; Qian, SX; Qiu, HX; Sheng, WY; Wu, HX; Xu, W; Zhang, R | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Eldering, E; Kater, AP; Tonino, SH; van Gelder, M; van Oers, MH | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Baurmann, H; Braess, J; Buechner, T; Haferlach, C; Hahn, J; Haude, KH; Hiddemann, W; Holler, E; Kolb, HJ; Oruzio, D; Schleuning, M; Schlimok, G; Schmid, C; Schwerdtfeger, R; Spiekermann, K; Tischer, J | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Burchert, A; Neubauer, A; Wilhelm, C | 1 |
| Solis, EC | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Borthakur, G; Cortes, J; Eghtedar, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E | 1 |
| Elonen, E; Honkanen, T; Jantunen, E; Jyrkkiö, S; Karjalainen-Lindsberg, ML; Kuittinen, O; Lehto, M; Mikkola, M; Poikonen, E; Räsänen, A; Räty, R; Rauhala, A; Rimpiläinen, J; Siitonen, S; Suominen, M; Vapaatalo, M | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B | 1 |
| Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| Bo, L; Chen, F; Fang, Y; Fu, J; Li, Y; Liang, A; Lu, H; Zhang, H; Zhu, D | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Alloush, H; Anderson, E; Conway, M; Lamont, J; Martin, A; Mehta, P; Ruddock, M; Salisbury, V; Smith, JG; Smith, MA | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G | 1 |
| Brychtova, Y; Doubek, M; Dusek, J; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M | 1 |
| Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B | 1 |
| Medeiros, BC | 1 |
| Aldoss, I; Haider, M; Ji, L; Pullarkat, V | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S | 1 |
| Bekele, N; Borthakur, G; Estey, E; Jabbour, EJ; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, WK; Ravandi-Kashani, F; Tsimberidou, AM | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Morgensztern, D; Peddi, PF; Peddi, S; Santos, ES | 1 |
| Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Estey, EE; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Koller, C; Luthra, R; O'Brien, S; Patel, K; Ravandi, F; Wang, X | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y | 1 |
| Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y | 1 |
| Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S | 1 |
| Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T | 1 |
| Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S | 1 |
| Alonzo, TA; Arceci, RJ; Balis, FM; Bunin, NJ; Castleberry, RP; Cheng, JW; Cooper, TM; Emanuel, PD; Gerbing, RB; Jayaprakash, N; Liu, YL; Loh, ML; Stieglitz, E; Ward, AF; Widemann, BC | 1 |
| Iliakis, G; Magin, S; Papaioannou, M; Saha, J; Staudt, C | 1 |
| Allegrini, S; Camici, M; Cividini, F; Filoni, DN; Pesi, R; Tozzi, MG | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Brennig, S; Czarnecki, K; Dilloo, D; Heinz, N; Heise, M; Heuser, M; Kaever, V; Kempf, H; Lachmann, N; Moritz, T; Phaltane, R; Schambach, A | 1 |
| Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M | 1 |
| Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K | 1 |
| Al-Ali, HK; Behre, G; Franke, GN; Hochhaus, A; Jentzsch, M; Klink, A; Niederwieser, D; Pfrepper, C; Sayer, HG; Schenk, T; Schwind, S | 1 |
| Chen, J; Hu, J; Huang, H; Huang, X; Jin, J; Li, J; Li, Y; Liang, Y; Ma, J; Sun, Y; Wang, C; Wang, J; Wang, L; Wu, D; Xiao, Y; Yu, K | 1 |
| Goto, H; Goto, S; Yokosuka, T | 1 |
| Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M | 1 |
| Akiyama, K; Aoki, T; Arakawa, Y; Hanada, R; Ikeda, Y; Koh, K; Mori, M; Sekinaka, Y | 1 |
| Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
| Cheng, H; Hu, X; Li, R; Lv, S; Song, X; Wang, J; Wang, L; Yang, J; Zhang, W | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Bonfigli, S; Careddu, MG; Coppola, L; Dessì, L; Dore, F; Dore, S; Fozza, C; Giannico, DB; Longinotti, M; Longu, F; Nieddu, RM; Pardini, S; Podda, L; Sotgiu, G | 1 |
| Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J | 1 |
| Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P | 1 |
| Curry, JL; Khan, M; Naqvi, K; Siddiqi, R | 1 |
| Brierley, CK; Eyre, TA | 1 |
| Buxhofer-Ausch, V; Geissler, K; Girschikofsky, M; Gleixner, K; Herndlhofer, S; Hoermann, G; Jaeger, U; Knoebl, P; Kundi, M; Machherndl-Spandl, S; Poehnl, R; Sliwa, T; Sperr, WR; Strecker, K; Valent, P; Weltermann, A | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Billingham, L; Brock, K; Copland, M; Siddique, S; Sirovica, M; Yap, C | 1 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G | 1 |
| Becktell, K; Burke, MJ; Houser, K | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V | 1 |
| Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H | 1 |
| Luo, W; Ni, X; Wei, J; Yu, H; Zou, X | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Li, LJ; Yu, K; Zhang, JY | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S | 1 |
| Bertrand, Y; Girard, S; Marceau-Renaut, A; Penel-Page, M; Plesa, A; Renard, C | 1 |
| Kolb, HJ; Schmid, C | 1 |
| de Castro, DG; Dietrich, S; Dreger, P; Dreyling, M; Grabe, N; Hermine, O; Hoster, E; Hüttl, K; Klapper, W; Kluin-Nelemans, HC; Müller-Tidow, C; Ott, G; Pott, C; Roider, T; Rosenwald, A; Stewart, JP; Wang, X | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Akiyama, M; Goto, H; Hasegawa, D; Honda, T; Kumamoto, T; Ogawa, S; Takagi, M; Terao, YM; Yamaoka, M; Yoshida, K | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Azarnoush, S; Dhunputh, C; Ducassou, S; Leverger, G; Merched, M; Pasquet, M; Petit, A; Strullu, M | 1 |
| Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X | 1 |
| Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I | 1 |
| Fu, Y; Gui, R; Guo, S; Li, Z; Song, Y; Wang, X; Zhan, X; Zhang, B; Zhang, W; Zhang, Y; Zhou, J; Zu, Y | 1 |
| Abuasab, T; Alvarado, Y; Borthakur, G; Brandt, MA; Daver, N; DiNardo, C; Haddad, FG; Kadia, T; Kantarjian, H; Pemmaraju, N; Ravandi, F; Senapati, J | 1 |
| Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ | 1 |
28 review(s) available for cytarabine and fludarabine
| Article | Year |
|---|---|
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
Evolution of the arabinosides and the pharmacology of fludarabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cytarabine; Humans; Leukemia; Vidarabine | 1994 |
Clinical experience with fludarabine in leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1994 |
The expanding role of fludarabine in hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Modulation of arabinosylcytosine metabolism during leukemia therapy.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Biotransformation; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia; Vidarabine | 1994 |
Antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance; Fluorouracil; Humans; Mercaptopurine; Methotrexate; Vidarabine | 1994 |
Fludarabine for treatment of adult acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Hematopoietic Cell Growth Factors; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Vidarabine | 1995 |
New chemotherapeutic agents in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine | 1996 |
Intracellular pharmacodynamics in leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Mitoxantrone; Vidarabine | 1996 |
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
Therapeutic options for acute myelogenous leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Prognosis; Topotecan; Vidarabine | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2002 |
[Clinical pharmacology of nucleoside analogues].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Biotransformation; Cytarabine; Cytidine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Half-Life; Humans; Male; Metabolic Clearance Rate; Neoplasm Proteins; Phosphorylation; Prodrugs; Vidarabine | 2002 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Breakage; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; DNA-Binding Proteins; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins; Remission Induction; Salvage Therapy; Thioguanine; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Vidarabine | 2003 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleosides; Phosphorylation; Vidarabine | 2005 |
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; Ifosfamide; Methotrexate; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Vidarabine; Vincristine | 2014 |
The FLAMSA concept-past and future.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
101 trial(s) available for cytarabine and fludarabine
| Article | Year |
|---|---|
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 1994 |
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1993 |
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Conjunctivitis; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1993 |
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine | 1996 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1998 |
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine | 1998 |
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine | 1998 |
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Blast Crisis; Cell Cycle; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Pilot Projects; Vidarabine | 1995 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1999 |
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Sex Factors; Vidarabine | 2001 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Rate; Vidarabine | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2002 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Cytarabine; Dexamethasone; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating; Remission Induction; Vidarabine; Vincristine | 2003 |
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine | 2003 |
[Modified FLAG regimen in the management of refractory acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2003 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 2003 |
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine | 2004 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Survival Analysis; Time Factors; Vidarabine | 2004 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Liposomes; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sepsis; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine | 2007 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine | 2008 |
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Research Design; Rituximab; Statistics, Nonparametric; Survival Analysis; Syndrome; Treatment Outcome; Vidarabine | 2008 |
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Lymphocyte Depletion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine | 2009 |
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 2009 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
[Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine; Young Adult | 2009 |
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2010 |
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytarabine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indicators and Reagents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Vidarabine | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine | 2013 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult | 2014 |
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine | 2014 |
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Isotretinoin; Leukemia, Myelomonocytic, Juvenile; Male; Middle Aged; Quinolones; Survival Rate; Vidarabine | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2016 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2015 |
Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Prospective Studies; Proto-Oncogene Proteins c-kit; Translocation, Genetic; Vidarabine; Young Adult | 2017 |
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Vidarabine | 2017 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Implementing the EffTox dose-finding design in the Matchpoint trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blast Crisis; Cytarabine; Humans; Idarubicin; Imidazoles; Models, Statistical; Outcome Assessment, Health Care; Pyridazines; Research Design; Vidarabine | 2017 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine | 2019 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine | 2020 |
The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Oxaliplatin; Prednisone; Primary Cell Culture; Rituximab; SAM Domain and HD Domain-Containing Protein 1; Tissue Array Analysis; Vidarabine; Vincristine | 2021 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine | 2022 |
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A
Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning | 2023 |
181 other study(ies) available for cytarabine and fludarabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
Topics: Animals; Anti-Bacterial Agents; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleosides; Phosphotransferases (Alcohol Group Acceptor); Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 2007 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Time Factors; Vidarabine | 1992 |
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Female; Humans; Hydroxyurea; Infusions, Intravenous; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine | 1992 |
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxyribonucleotides; Drug Interactions; Guanosine Triphosphate; Humans; Leukemia; Phosphorylation; Phosphotransferases; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate | 1989 |
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1988 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Topics: Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Nucleotides; Vidarabine | 1987 |
Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Neutropenia; Pancreatic Diseases; Syndrome; Vidarabine | 1993 |
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Vidarabine | 1994 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1995 |
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Administration Schedule; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine | 1993 |
A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Methylcellulose; Vidarabine | 1993 |
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 1993 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biotransformation; Breast Neoplasms; Carcinoma, Small Cell; Cladribine; Colonic Neoplasms; Cytarabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genetic Vectors; Humans; Lung Neoplasms; Moloney murine leukemia virus; Phosphorylation; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vidarabine | 1996 |
Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Survival; Cytarabine; Deoxycytidine; Drug Interactions; Gemcitabine; HL-60 Cells; Humans; Thymidine; Vidarabine | 1996 |
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Topics: Antineoplastic Agents; Cell Cycle; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Binding; Tumor Cells, Cultured; Vidarabine | 1996 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.
Topics: Adenosine; Amino Acid Sequence; Animals; Antineoplastic Agents; Carrier Proteins; Cladribine; Cloning, Molecular; Cytarabine; Databases, Factual; DNA, Complementary; Equilibrative Nucleoside Transporter 1; Humans; Membrane Proteins; Molecular Sequence Data; Nucleosides; Oocytes; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Tissue Distribution; Uridine; Vidarabine; Xenopus | 1997 |
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Topics: Antineoplastic Agents; Binding Sites; Cytarabine; Deoxycytidine; DNA Repair; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 1997 |
Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy.
Topics: Adult; Cladribine; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Bayesian interim analysis of phase II cancer clinical trials.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Risk Factors; Time Factors; Vidarabine | 1998 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; K562 Cells; Vidarabine | 1996 |
Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia; Terminology as Topic; Vidarabine; Vidarabine Phosphate | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
Topics: Antineoplastic Agents; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Phenotype; Vidarabine | 1999 |
Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells.
Topics: Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured; Vidarabine | 1999 |
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine | 1999 |
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine | 2000 |
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Ribonucleotide Reductases; Vidarabine | 2000 |
Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Vidarabine | 1999 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |
Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells.
Topics: Antineoplastic Agents; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 2001 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Neoplasms, Multiple Primary; Remission Induction; Vidarabine | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2001 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Interferon-alpha; Lymphoma, Follicular; Opportunistic Infections; Prednisone; Salvage Therapy; Teniposide; Toxoplasmosis, Cerebral; Vidarabine | 2002 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Colitis; Cytarabine; Cytomegalovirus Infections; Female; Humans; Middle Aged; Mitoxantrone; Vidarabine | 2002 |
Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Factor VIIa; Fatal Outcome; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Lung Diseases; Pneumothorax; Pulmonary Alveoli; Recombinant Proteins; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Apoptosis; Cisplatin; Cytarabine; Deoxyadenosines; DNA Fragmentation; Doxorubicin; Endodeoxyribonucleases; Etoposide; Humans; In Situ Nick-End Labeling; Leukemia, Mast-Cell; Microscopy, Electron; Neoplasm Proteins; Tumor Cells, Cultured; Vidarabine; Vincristine | 2003 |
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2003 |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 3; Caspases; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 2003 |
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Middle Aged; Time Factors; Transplantation, Autologous; Vidarabine | 2004 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Rituximab; Treatment Failure; Vidarabine | 2004 |
Fatal peripheral neuropathy following FLA chemotherapy.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Interactions; Fatal Outcome; Humans; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrimidines; Triazoles; Vidarabine; Voriconazole | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Tumor Cells, Cultured; Vidarabine | 2004 |
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine | 2004 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Teniposide; Treatment Outcome; Vidarabine | 2005 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.
Topics: Animals; Binding, Competitive; Biotransformation; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; DNA; Drug Interactions; Drug Resistance, Neoplasm; Hydroxyurea; Mice; Nucleosides; Vidarabine | 2005 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Vidarabine | 2006 |
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine | 2006 |
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine | 2006 |
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Stem Cells; Treatment Outcome; Vidarabine | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Improved outcome after relapse in children with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2007 |
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Chromosome Breakage; Chromosome Fragility; Cyclophosphamide; Cytarabine; Fanconi Anemia; Female; Humans; Male; Myeloablative Agonists; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine | 2007 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Saudi Arabia; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cord Blood Stem Cell Transplantation; Cytarabine; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Kinetics; Male; Middle Aged; Risk Assessment; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 2008 |
Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Cytarabine; Cytochrome P-450 CYP3A; Drug Delivery Systems; Infusions, Intravenous; Liver; Liver Neoplasms; Male; Mice; Nucleosides; Prodrugs; Thymidine; Tissue Distribution; Vidarabine | 2009 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Retrospective Studies; Translocation, Genetic; Vidarabine | 2012 |
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine | 2013 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinofuranosylcytosine Triphosphate; Bacterial Proteins; Biosensing Techniques; Cell Line, Tumor; Cytarabine; HL-60 Cells; Humans; K562 Cells; Leukemia; Luminescent Measurements; Luminescent Proteins; Treatment Outcome; Vidarabine | 2013 |
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine | 2013 |
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Salvage Therapy; Vidarabine | 2014 |
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Secondary Prevention; Survival Analysis; Vidarabine | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Vidarabine | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
[Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
Topics: Adolescent; Adult; Allografts; Cytarabine; Disease-Free Survival; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Vidarabine; Young Adult | 2014 |
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation | 2014 |
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine | 2015 |
Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside-Nucleoside Analogue Radiosensitization.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cytarabine; DNA Breaks, Double-Stranded; DNA Repair; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Green Fluorescent Proteins; Homologous Recombination; Humans; Microscopy, Confocal; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Vidarabine; X-Rays | 2015 |
IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Cell Survival; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance; Gemcitabine; Green Fluorescent Proteins; Guanosine Monophosphate; HEK293 Cells; Humans; Immunoblotting; Inosine Monophosphate; Nucleotides; Phosphorylation; Prodrugs; Substrate Specificity; Vidarabine | 2015 |
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Topics: Antineoplastic Agents; Bone Marrow; Cladribine; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Genetic Therapy; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Vidarabine | 2015 |
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine | 2015 |
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Topics: Adolescent; Adult; Anthracyclines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; China; Consolidation Chemotherapy; Cytarabine; Female; Humans; Incidence; Infant; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prospective Studies; Survival Rate; Vidarabine; Young Adult | 2016 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Cytarabine; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Extensive ulcerated lesions in a patient with cutaneous myeloid sarcoma responded to twice-daily fludarabine and cytarabine regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cytarabine; Drug Administration Schedule; Fatal Outcome; Humans; Male; Positron Emission Tomography Computed Tomography; Sarcoma, Myeloid; Skin Neoplasms; Skin Ulcer; Treatment Outcome; Vidarabine | 2018 |
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hearing Loss, Unilateral; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemic Infiltration; Male; Orbit; Tumor Lysis Syndrome; Vidarabine | 2017 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Down Syndrome; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Vidarabine; Vorinostat | 2019 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine | 2018 |
Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Purines; Remission Induction; RNA, Long Noncoding; Vidarabine | 2018 |
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine | 2019 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2020 |
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine | 2021 |
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine | 2021 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2021 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
Topics: Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; DNA-Binding Proteins; Etoposide; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; Liver Neoplasms; Lymphoma, T-Cell; PAX5 Transcription Factor; Prognosis; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins; Splenic Neoplasms; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2022 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Single-dose (4.5 mg/m
Topics: Adult; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Vidarabine | 2022 |
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies | 2023 |
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Vidarabine | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning | 2023 |